Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors

Ruoyang Chen; Dawei Li; Ming Zhang; Xiaodong Yuan

doi:10.12659/AOT.933313

07 September 2021: Original Paper

Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors

Ruoyang Chen ^BCEF* , Dawei Li ^BCDFG* , Ming Zhang ^AC , Xiaodong Yuan ^ADEF*

DOI: 10.12659/AOT.933313

Ann Transplant 2021; 26:e933313

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 2 The serum creatine levels of patients were followed up at days 14 and 90 after renal transplant surgery (26 patients were enrolled and 24 patients completed the follow-up).

Back to the Article

Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors

Your Privacy